



EVIDENCE MAP OF COSTS STUDIES IN CYSTIC FIBROSIS SINCE 1960

Alison Martin¹ ¹Crystallise Ltd, Essex, UK alison.martin@crystallise.com

Objectives

To create an evidence map of studies reporting the direct and indirect costs associated with cystic fibrosis, and the geographical settings in which these studies were conducted.

Methods

We searched the heoro.com database (www.heoro.com) for costs studies in cystic fibrosis published between 2000 and 17 May 2017. We analysed the abstracts identified by the search to determine the different types of costs reported across the range of geographical locations and interventions. We presented the findings as an

Results

Map of geographical location by type of costs

	Direct costs	Indirect costs		
Australia	7	1		
Brazil	1	0		
Canada	6	1		
Denmark	1	0		
France	3	1		
Germany	3	0		
International	9	1		
Netherlands	2	1		
New Zealand	1	0		
UK	13	1		
USA	15	1		

Map of intervention by type of costs

	Direct costs	Indirect costs
All healthcare	10	2
Antibiotics	12	1
Bronchiolar lavage	1	0
Denufosol	1	0
Diet	1	0
Inpatient care	3	0
Ivacaftor	1	0
Lung transplant	4	0
Outpatient care	1	0
Physiotherapy	2	0
RhDNAse	4	1
Screening	18	4
Other/ none/ unclear	6	0

Map of intervention by publication date

	1960-1999	2000-2004	2005-2009	2010-2014	2015-2017	
All healthcare	0	5	3	0	2	
Antibiotics	0	1	5	4	2	
Bronchiolar lavage	0	0	0	1	0	
Denufosol	0	0	0	1	0	
Diet	0	0	0	1	0	
Inpatient care	0	2	0	1	0	
Ivacaftor	0	0	0	1	0	
Lung transplant	0	2	2	0	0	
Outpatient care	0	0	0	1	0	
Physiotherapy	0	0	0	2	0	
RhDNAse	0	4	0	0	0	
Screening	0	4	5	7	2	
Other/ none/ unclear	0	1	1	2	0	

Map of intervention by geographical location

	Australia	Brazil	Canada	Denmark	France	Germany	International	Netherlands	New Zealand	UK	USA
All healthcare	0	0	1	0	2	1	4	0	0	1	1
Antibiotics	0	0	1	0	0	1	2	0	0	5	3
Bronchiolar lavage	1	0	0	0	0	0	0	0	1	0	0
Denufosol	0	0	0	0	0	0	0	0	0	0	1
Diet	0	0	0	0	0	0	0	0	0	1	0
Inpatient care	1	0	0	0	0	0	0	0	0	0	2
Ivacaftor	0	0	0	0	0	0	0	0	0	1	0
Lung transplant	1	0	1	0	0	0	1	0	0	0	1
Outpatient care	0	0	0	0	0	1	0	0	0	0	0
Physiotherapy	0	0	0	0	0	0	0	0	0	2	0
RhDNAse	0	0	0	0	0	0	0	0	0	3	1
Screening	3	1	1	1	1	0	3	2	0	1	5
Other/ none/ unclear	1	0	2	0	0	0	0	0	0	0	1

Numbers refer to number of studies identified for each category. Where a study is set in two or three locations, these are all listed separately. Studies set in five or more jurisdictions, or systematic reviews are classified as International. Studies are mapped to all relevant subcategories.

Conclusions

As with many diseases, there is a relative lack of published data on indirect costs of cystic fibrosis, and two-thirds of studies reporting cost data were from just four jurisdictions: Australia, Canada, the UK and the USA.

Crystallise Ltd. Unit 21 Thames Enterprise Centre, Thames Industrial Park, East Tilbury, Essex RM18 8RH , UK Tel: +44 (0)1375 488020

For a copy of this poster or the interactive evidence map, email: alison.martin@crystallise.com



Presented at the ISPOR 20th European Congress 4-8November 2017, Glasgow, Scotland

www.crystallise.com www.heoro.com